SHIM
PACB icon

Stone House Investment Management’s Pacific Biosciences PACB Stock Holding History

Stone House Investment Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34K Sell
797
-700
-47% -$1.02K ﹤0.01% 823
2026
Q1 		$1.98K Buy
+1,497
New +$2.68K ﹤0.01% 595

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Stone House Investment Management's PACB Position: Q2 2026 in Review

Stone House Investment Management reduced its Pacific Biosciences (PACB) stake by 47% in Q2 2026, selling an estimated $1.02K and leaving 797 shares worth $1.34K. The position accounts for ﹤0.01% of the portfolio, ranked #823.

Stone House Investment Management first reported a position in PACB in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.98K in Q1 2026. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Stone House Investment Management held 797 shares of Pacific Biosciences worth $1.34K as of Q2 2026.
  • Stone House Investment Management sold 700 Pacific Biosciences shares in Q2 2026, an estimated $1.02K.
  • Pacific Biosciences made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #823 holding.
  • Stone House Investment Management first reported a position in Pacific Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Stone House Investment Management's Pacific Biosciences position peaked at $1.98K in Q1 2026.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.